Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Retrogenix Limited, an early-stage contract research organization (CRO) providing specialized bioanalytical services utilizing its proprietary cell microarray technology. Based in the United Kingdom, Retrogenix offers cell microarray services for target receptor identification, off-target profiling, and target deconvolution on a wide range of novel therapeutics including biologics, cell therapies, and small molecules.
Read the full article: Charles River Laboratories Acquires Retrogenix //
Source: https://www.businesswire.com/news/home/20210331005133/en/Charles-River-Laboratories-Acquires-Retrogenix